The FDA has designated Stoboclo and Osenvelt as interchangeable biosimilars to the reference products Prolia and Xgeva, respectively.

The FDA has designated Conexxence and Bomyntra as interchangeable biosimilars to the reference products Prolia and Xgeva, ...

The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.

Once a person loses bone density, they typically cannot regain it. However, they may be able to prevent further bone density loss through lifestyle adjustments, such as getting sufficient exercise, ...

Credit: Celltrion. The denosumab biosimilars Stoboclo and Osenvelt have the same indications as the reference products Prolia and Xgeva, respectively. Patient support and financial assistance are ...

Please provide your email address to receive an email when new articles are posted on . Samsung Bioepis received approval for two biosimilars of denosumab that are interchangeable with Prolia and ...

(RTTNews) - Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Bosaya ...

The US Food and Drug Administration (FDA) has added a boxed warning to the label of the osteoporosis drug denosumab (Prolia) about increased risk for severe hypocalcemia in patients with advanced ...